{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT04951219","orgStudyIdInfo":{"id":"MGL-3196-18"},"organization":{"fullName":"Madrigal Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)","officialTitle":"A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)"},"statusModule":{"statusVerifiedDate":"2025-07","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-07-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-04","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-06-18","studyFirstSubmitQcDate":"2021-07-02","studyFirstPostDateStruct":{"date":"2021-07-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-07-30","lastUpdatePostDateStruct":{"date":"2025-08-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Madrigal Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)"},"conditionsModule":{"conditions":["Non-Alcoholic Fatty Liver Disease"],"keywords":["NAFLD","NASH","Hyperlipidemia","Resmetirom","Thyroid hormone receptor beta","Hepatic","Fibrosis","NASH resolution","Thyroid hormone receptor agonist","Cardiovascular","Dyslipidemia","Fatty liver disease","Nonalcoholic steatohepatitis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","maskingDescription":"Select patients will be randomized in 1:1 manner to a double-blind, 12-week lead-in treatment period. Only investigators, patients, and the Sponsor will be blinded to treatment assignment during the double-blind treatment period.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":1000,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Double-blind 80 mg Daily","type":"EXPERIMENTAL","description":"For patients assigned to double-blind treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, double-blind resmetirom 80 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52","interventionNames":["Drug: Resmetirom"]},{"label":"Double-blind 100 mg Daily","type":"EXPERIMENTAL","description":"For patients assigned to double-blind treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, double-blind resmetirom 100 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52","interventionNames":["Drug: Resmetirom"]},{"label":"Open-label","type":"EXPERIMENTAL","description":"For patients assigned to open-label treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, open-label resmetirom at same dose as MGL-3196-14 for an additional 52 weeks. NASH cirrhosis patients may receive open-label resmetirom for an additional 52 weeks (ie, 52 weeks in MGL-3196-14 and 104 weeks in MGL-3196-18).","interventionNames":["Drug: Resmetirom"]},{"label":"Open-Label 80 mg","type":"EXPERIMENTAL","description":"For patients with NASH cirrhosis who were screen failures from MGL-3196-11, open-label resmetirom 80 mg for 104 weeks","interventionNames":["Drug: Resmetirom"]},{"label":"Open Label 100 mg","type":"EXPERIMENTAL","description":"For patients without NASH cirrhosis who were screen failures from MGL-3196-11, open-label resmetirom 100 mg for 52 weeks","interventionNames":["Drug: Resmetirom"]},{"label":"Open-Label 40 mg","type":"EXPERIMENTAL","description":"For NASH cirrhosis patients who enter MGL-3196-18 directly or were screen failures from MGL-3196-19, open-label resmetirom 40 mg for 104 weeks","interventionNames":["Drug: Resmetirom"]}],"interventions":[{"type":"DRUG","name":"Resmetirom","description":"Tablet","armGroupLabels":["Double-blind 100 mg Daily","Double-blind 80 mg Daily","Open Label 100 mg","Open-Label 40 mg","Open-Label 80 mg","Open-label"],"otherNames":["MGL-3196"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The effect of once daily, oral administration of resmetirom on the incidence of adverse events.","timeFrame":"52 weeks"}],"secondaryOutcomes":[{"measure":"Percent change in the hepatic fat fraction as determined by MRI-PDFF from baseline","timeFrame":"16 weeks"},{"measure":"Percent change in the hepatic fat fraction as determined by MRI-PDFF from baseline","timeFrame":"52 weeks"},{"measure":"Percent change in LDL-C from baseline","timeFrame":"28 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* For patients who completed MAESTRO-NAFLD-1, completed the Week 52 visit, and completed the Week 56 visit within 90 days of the Extension Day 1 visit, and are willing to participate in MAESTRO-NAFLD-OLE and provide written informed consent.\n* For patients who screen failed MAESTRO-NASH, must provide written informed consent for MAESTRO-NAFLD-OLE and must have screened and met all eligibility requirements for MAESTRO-NASH within 90 days of the Extension Day 1 visit for MAESTRO-NAFLD-OLE and have a liver biopsy that is ineligible for MAESTRO-NASH within 6 months of the Extension Day 1 visit. Eligible liver biopsy for MAESTRO-NAFLD-OLE must have one of the following results:\n\n  * NAS = 3, steatosis 1, ballooning 1, inflammation 1, OR NAS = 3, ballooning 0, with F1B, F2 or F3\n  * NAS ≥ 4, at least 1 in all NAS components, F1A or F1C, PRO-C3 ≤ 14 (NASH, but ineligible for MAESTRO-NASH)\n  * Compensated NASH cirrhosis based on biopsy at screening of MAESTRO-NASH and baseline of MAESTRO-NAFLD-OLE, including Child Pugh-A (score 5-6), MELD \\<12, albumin ≥3.2, and bilirubin \\<2\n* For patients who screen failed from MAESTRO-NASH OUTCOMES and de novo patients, must have documented CP-A/B (score \\<8) NASH cirrhosis (including minimal decompensation) and MELD \\<15 unless MELD \\>=15 based on non-cirrhotic parameters. MAESTRO-NASH OUTCOMES screen failures must have screened and met all eligibility requirements for MAESTRO-NASH OUTCOMES within 90 days of the Extension Day 1 visit for MAESTRO-NAFLD-OLE .\n\nExclusion Criteria:\n\n* A history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to Extension Day 1.\n* Diagnosis of hepatocellular carcinoma or other carcinomas that may prevent participation in the Extension study.\n* Chronic liver diseases\n* Has an active autoimmune disease\n* Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Rebecca Taub, MD","affiliation":"Madrigal Pharmaceuticals, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Central Research Associates","city":"Birmingham","state":"Alabama","zip":"35205","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Arizona Liver Health - Chandler","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"East Valley Family Physicians","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"The Institute For Liver Health - Glendale","city":"Glendale","state":"Arizona","zip":"85306","country":"United States","geoPoint":{"lat":33.53865,"lon":-112.18599}},{"facility":"The Institute For Liver Health - Tucson","city":"Tucson","state":"Arizona","zip":"85711","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Adobe Gastroenterology","city":"Tucson","state":"Arizona","zip":"85712","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Arkansas Gastroenterology","city":"North Little Rock","state":"Arkansas","zip":"72117","country":"United States","geoPoint":{"lat":34.76954,"lon":-92.26709}},{"facility":"Fresno Clinical Research Center","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"National Research Institute - Huntington Park","city":"Huntington Park","state":"California","zip":"90255","country":"United States","geoPoint":{"lat":33.98168,"lon":-118.22507}},{"facility":"Ruane Clinical Research Group","city":"Los Angeles","state":"California","zip":"90036","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Cedars-Sinai Medical Center","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"National Research Institute - Los Angeles","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"National Research Institute - Panorama City","city":"Panorama City","state":"California","zip":"91402","country":"United States","geoPoint":{"lat":34.22473,"lon":-118.44981}},{"facility":"San Fernando Valley Health Institute","city":"West Hills","state":"California","zip":"91307","country":"United States","geoPoint":{"lat":34.19731,"lon":-118.64398}},{"facility":"South Denver Gastroenterology - Swedish Medical Center Office","city":"Englewood","state":"Colorado","zip":"80113","country":"United States","geoPoint":{"lat":39.64777,"lon":-104.98776}},{"facility":"Excel Medical Clinical Trials","city":"Boca Raton","state":"Florida","zip":"33434","country":"United States","geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"Covenant Research","city":"Fort Myers","state":"Florida","zip":"33912","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Velocity Clinical Research, Hallandale Beach (MD Clinical)","city":"Hallandale","state":"Florida","zip":"33009","country":"United States","geoPoint":{"lat":25.9812,"lon":-80.14838}},{"facility":"Floridian Clinical Research","city":"Hialeah","state":"Florida","zip":"33016","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Nature Coast Clinical Research - Inverness","city":"Inverness","state":"Florida","zip":"34452","country":"United States","geoPoint":{"lat":28.83582,"lon":-82.33037}},{"facility":"Jacksonville Center for Clinical Research","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Florida Research Institute","city":"Lakewood Rch","state":"Florida","zip":"34211","country":"United States","geoPoint":{"lat":27.3863,"lon":-82.4332}},{"facility":"Orlando Research Center","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Progressive Medical Research","city":"Port Orange","state":"Florida","zip":"32127","country":"United States","geoPoint":{"lat":29.13832,"lon":-80.99561}},{"facility":"Covenant Research","city":"Sarasota","state":"Florida","zip":"34240","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"The Villages Research Center","city":"The Villages","state":"Florida","zip":"32162","country":"United States","geoPoint":{"lat":28.93408,"lon":-81.95994}},{"facility":"Gastrointestinal Specialists of Georgia","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"East-West Medical Research Institute","city":"Honolulu","state":"Hawaii","zip":"96814","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Chicago Research Center","city":"Chicago","state":"Illinois","zip":"60602","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Northwestern Memorial Physicians Group","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Iowa Diabetes Research","city":"West Des Moines","state":"Iowa","zip":"50265","country":"United States","geoPoint":{"lat":41.57721,"lon":-93.71133}},{"facility":"Kansas Medical Clinic - Gastroenterology","city":"Topeka","state":"Kansas","zip":"66606","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"L-MARC Research Center","city":"Louisville","state":"Kentucky","zip":"40213","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Digestive Health Center of Louisiana","city":"Baton Rouge","state":"Louisiana","zip":"70809","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Tandem Clinical Research - New Orleans Area Site","city":"Marrero","state":"Louisiana","zip":"70072","country":"United States","geoPoint":{"lat":29.89937,"lon":-90.10035}},{"facility":"Clinical Trials of America","city":"West Monroe","state":"Louisiana","zip":"71291","country":"United States","geoPoint":{"lat":32.51848,"lon":-92.14764}},{"facility":"Gastrointestinal Associates & Endoscopy Center - Flowood","city":"Flowood","state":"Mississippi","zip":"39232","country":"United States","geoPoint":{"lat":32.30959,"lon":-90.13898}},{"facility":"Southern Therapy and Advanced Research","city":"Jackson","state":"Mississippi","zip":"39216","country":"United States","geoPoint":{"lat":32.29876,"lon":-90.18481}},{"facility":"Kansas City Research Institute","city":"Kansas City","state":"Missouri","zip":"64131","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Henderson Research Center","city":"Henderson","state":"Nevada","zip":"89052","country":"United States","geoPoint":{"lat":36.0397,"lon":-114.98194}},{"facility":"Clarity Clinical Research","city":"East Syracuse","state":"New York","zip":"13057","country":"United States","geoPoint":{"lat":43.06534,"lon":-76.07853}},{"facility":"Mount Sinai Health System","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Duke University Medical Center","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Cumberland Research Associates","city":"Fayetteville","state":"North Carolina","zip":"28304","country":"United States","geoPoint":{"lat":35.05266,"lon":-78.87836}},{"facility":"Diabetes and Endocrinology Consultants","city":"Morehead City","state":"North Carolina","zip":"28557","country":"United States","geoPoint":{"lat":34.72294,"lon":-76.72604}},{"facility":"Aventiv Research Columbus","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Awasty Research Network","city":"Marion","state":"Ohio","zip":"43302","country":"United States","geoPoint":{"lat":40.58867,"lon":-83.12852}},{"facility":"Premier Medical Group - Clarksville - Dunlop Lane","city":"Clarksville","state":"Tennessee","zip":"37040","country":"United States","geoPoint":{"lat":36.52977,"lon":-87.35945}},{"facility":"Gastro One - Germantown Office - Wolf Park Drive","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"Pinnacle Clinical Research - Austin","city":"Austin","state":"Texas","zip":"78746","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"The Liver Institute At Methodist Dallas","city":"Dallas","state":"Texas","zip":"75203","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Dallas Research Center","city":"Dallas","state":"Texas","zip":"75234","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Liver Center of Texas","city":"Dallas","state":"Texas","zip":"75234","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"South Texas Research Institute","city":"Edinburg","state":"Texas","zip":"78539","country":"United States","geoPoint":{"lat":26.30174,"lon":-98.16334}},{"facility":"Texas Digestive Disease Consultants","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Liver Associates of Texas","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Doctor's Hospital at Renaissance","city":"McAllen","state":"Texas","zip":"78504","country":"United States","geoPoint":{"lat":26.20341,"lon":-98.23001}},{"facility":"Plano Research Center","city":"Plano","state":"Texas","zip":"75093","country":"United States","geoPoint":{"lat":33.01984,"lon":-96.69889}},{"facility":"Texas Liver Institute/American Research Corporation","city":"San Antonio","state":"Texas","zip":"78215","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Pinnacle Clinical Research - San Antonio","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"San Antonio Research Center","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Texas Digestive Disease Consultants - San Marcos","city":"San Marcos","state":"Texas","zip":"78666","country":"United States","geoPoint":{"lat":29.88327,"lon":-97.94139}},{"facility":"Impact Research Institute","city":"Waco","state":"Texas","zip":"76710","country":"United States","geoPoint":{"lat":31.54933,"lon":-97.14667}},{"facility":"Texas Digestive Disease Consultants - Bay Area Houston Endoscopy Center","city":"Webster","state":"Texas","zip":"77598","country":"United States","geoPoint":{"lat":29.53773,"lon":-95.11826}},{"facility":"Wasatch Peak Family Practice","city":"Layton","state":"Utah","zip":"84041","country":"United States","geoPoint":{"lat":41.06022,"lon":-111.97105}},{"facility":"Salt Lake City Research Center","city":"Murray","state":"Utah","zip":"84123","country":"United States","geoPoint":{"lat":40.66689,"lon":-111.88799}},{"facility":"Bon Secours Liver Institute of Richmond","city":"Richmond","state":"Virginia","zip":"23226","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"National Clinical Research - Richmond","city":"Richmond","state":"Virginia","zip":"23294","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Virginia Commonwealth University School of Medicine","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Liver Institute Northwest","city":"Seattle","state":"Washington","zip":"98105","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Fundacion de Investigacion de Diego","city":"San Juan","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}}]},"referencesModule":{"references":[{"pmid":"37786277","type":"DERIVED","citation":"Harrison SA, Ratziu V, Anstee QM, Noureddin M, Sanyal AJ, Schattenberg JM, Bedossa P, Bashir MR, Schneider D, Taub R, Bansal M, Kowdley KV, Younossi ZM, Loomba R. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2024 Jan;59(1):51-63. doi: 10.1111/apt.17734. Epub 2023 Oct 2."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D065626","term":"Non-alcoholic Fatty Liver Disease"},{"id":"D006949","term":"Hyperlipidemias"},{"id":"D018382","term":"Thyroid Hormone Resistance Syndrome"},{"id":"D005355","term":"Fibrosis"},{"id":"D050171","term":"Dyslipidemias"}],"ancestors":[{"id":"D005234","term":"Fatty Liver"},{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D052439","term":"Lipid Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D006981","term":"Hyperthyroxinemia"},{"id":"D013959","term":"Thyroid Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C588408","term":"resmetirom"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05500222","orgStudyIdInfo":{"id":"MGL-3196-19"},"organization":{"fullName":"Madrigal Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)","officialTitle":"A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)"},"statusModule":{"statusVerifiedDate":"2025-06","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-08-26","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-08-11","studyFirstSubmitQcDate":"2022-08-11","studyFirstPostDateStruct":{"date":"2022-08-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-06-09","lastUpdatePostDateStruct":{"date":"2025-06-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Madrigal Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.","detailedDescription":"This is a multi-national, multicenter, double-blind, randomized, placebo-controlled study in participants with well-compensated NASH cirrhosis. Participants will be randomized 3:1 in a blinded manner to receive 80 mg resmetirom or matching placebo given orally once daily in the morning for the duration of the study (until the required number of Composite Clinical Outcome events are achieved). Composite Clinical Outcome events are defined as any of the following: liver-related and CV mortality, liver transplant, and significant hepatic events, including potential hepatic decompensation events (ascites, hepatic encephalopathy, or gastroesophageal variceal hemorrhage), and confirmed increase of Model for End-stage Liver Disease (MELD) score from \\<12 to ≥15. The study comprises an up to 60-day screening period and an approximately 3-year treatment period."},"conditionsModule":{"conditions":["NASH","Cirrhosis, Liver"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":700,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Resmetirom","type":"ACTIVE_COMPARATOR","description":"80 mg daily","interventionNames":["Drug: Resmetirom"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"matching placebo daily","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Resmetirom","description":"Randomized 80 mg","armGroupLabels":["Resmetirom"],"otherNames":["MGL-3196"]},{"type":"DRUG","name":"Placebo","description":"randomized matching placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence Of adjudicated Composite Clinical Outcome event","description":"Any event of all-cause mortality, liver transplant, ascites, hepatic encephalopathy, gastroesophageal variceal hemorrhage, and confirmed increase of MELD score from \\<12 to \\>/= 15 due to liver disease","timeFrame":"Baseline up to Month 36"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Definitive (by histologic documentation) or probable NASH as causative agent for cirrhosis, following a modified version of the NASH Cirrhosis: Liver Forum Consensus Definitions for Clinical Trials.\n* a. Most recent biopsy (within last 5 years) shows cirrhosis with a NAS of ≥ 2, and at least two components: one being steatosis and at least one other component; OR NAS of ≥ 2, if steatosis = 0 or is ungraded with inflammation and/or ballooning, eligible with an MRI-PDFF \\>5%. If steatosis and ballooning and/or steatosis and inflammation are noted by the local pathologist, then the biopsy qualifies even if a NAS is not provided (Approximately 70% of the study patient population) b. Historical biopsy (within last 5 years) showed NASH with significant fibrosis with pathology report documenting \"F2\" or \"F3\", with at least steatosis either by biopsy with no minimal percentage required or by MRI-PDFF \\>5%, AND inflammation or ballooning. Now with cirrhosis, either by clinical history or current features, imaging, noninvasive tests, or biopsy (see Appendix 7) (Up to approximately 20% of study patient population) c. Historical biopsy (within last 5 years) shows steatosis. Pathology report documents steatosis with no minimal percentage required. Now with cirrhosis, either by clinical history or current features, imaging, noninvasive tests, or biopsy (see Appendix 7). Prescreening metabolic risk factors must include obesity and/or T2D. (Up to approximately 10% of study patient population.)\n* Well-compensated NASH cirrhosis at screening and baseline with Child-Pugh A (score of 5-6) (no history of hepatic decompensation event).\n* At least 3 metabolic risk factors\n* Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) that is obtained during the Screening period or a historic MRI-PDFF at ≤8 weeks old at the time of randomization with no weight change ≥5% weight change in that interval.\n* MRE ≥4.2 where MRE is available.\n* Enhanced liver function (ELF) ≥9.8, only if MRE is unavailable or contraindicated.\n\nExclusion Criteria:\n\n* Participants with a chronic liver diseases other than NASH cirrhosis, such as primary biliary cholangitis, primary sclerosing cholangitis, Hepatitis B positive, Hepatitis C, history or evidence of current active autoimmune hepatitis, history or evidence of Wilson's disease, history or evidence of alpha-1-antitrypsin deficiency, history or evidence of genetic hemochromatosis (hereditary, primary), evidence of drug-induced liver disease, as defined on the basis of typical exposure and history, known bile duct obstruction, or suspected or confirmed liver cancer, are excluded.\n* Participants with MELD score ≥12 due to liver disease are excluded.\n* Participants with a history of hepatic decompensation or impairment are excluded.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Thomas Hare","affiliation":"VP, Clinical Research","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Alabama at Birmingham (UAB)","city":"Birmingham","state":"Alabama","zip":"35249","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Arizona Liver Health - Chandler","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"Arizona Liver Health - Peoria","city":"Peoria","state":"Arizona","zip":"85381","country":"United States","geoPoint":{"lat":33.5806,"lon":-112.23738}},{"facility":"Adobe Clinical Research","city":"Tucson","state":"Arizona","zip":"85712","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Arizona Liver Health - Tucson","city":"Tucson","state":"Arizona","zip":"85712","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Arkansas Diagnostic Center/Liver Wellness Center","city":"Little Rock","state":"Arkansas","zip":"72205-6414","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"facility":"Arkansas Gastroenterology","city":"North Little Rock","state":"Arkansas","zip":"72117","country":"United States","geoPoint":{"lat":34.76954,"lon":-92.26709}},{"facility":"Southern California Research Center","city":"Coronado","state":"California","zip":"92118","country":"United States","geoPoint":{"lat":32.68589,"lon":-117.18309}},{"facility":"University of California, San Francisco-Fresno","city":"Fresno","state":"California","zip":"93701","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"Univ. of California San Diego School of Medicine","city":"La Jolla","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Keck School of Medicine of USC","city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"California Liver Research Institute","city":"Pasadena","state":"California","zip":"91105","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"South Denver Gastroenterology","city":"Englewood","state":"Colorado","zip":"80113","country":"United States","geoPoint":{"lat":39.64777,"lon":-104.98776}},{"facility":"Hi Tech and Global Research","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Top Medical Research Inc","city":"Cutler Bay","state":"Florida","zip":"33189","country":"United States","geoPoint":{"lat":25.5783,"lon":-80.3377}},{"facility":"Covenant Research - Fort Myers","city":"Fort Myers","state":"Florida","zip":"33912","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"Nature Coast Clinical Research - Inverness","city":"Inverness","state":"Florida","zip":"34452","country":"United States","geoPoint":{"lat":28.83582,"lon":-82.33037}},{"facility":"Jacksonville Center for Clinical Research","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Ocala GI Research DBA Lake Center for Clinical Research","city":"Lady Lake","state":"Florida","zip":"32159","country":"United States","geoPoint":{"lat":28.91749,"lon":-81.92286}},{"facility":"Florida Research Institute","city":"Lakewood Rch","state":"Florida","zip":"34238","country":"United States","geoPoint":{"lat":27.3863,"lon":-82.4332}},{"facility":"Sanchez Clinical Research","city":"Miami","state":"Florida","zip":"33157","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Ocala GI Research","city":"Ocala","state":"Florida","zip":"34471","country":"United States","geoPoint":{"lat":29.1872,"lon":-82.14009}},{"facility":"St Johns Center for Clinical Research","city":"Saint Augustine","state":"Florida","zip":"32086","country":"United States","geoPoint":{"lat":29.89469,"lon":-81.31452}},{"facility":"Covenant Research","city":"Sarasota","state":"Florida","zip":"34240","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"International Center for Research","city":"Tampa","state":"Florida","zip":"33614","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Florida Medical Clinic","city":"Zephyrhills","state":"Florida","zip":"33542","country":"United States","geoPoint":{"lat":28.23362,"lon":-82.18119}},{"facility":"Summit Clinical Research","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"Gastrointestinal Specialists of Georgia","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"Kansas Medical Clinic - Gastroenterology","city":"Topeka","state":"Kansas","zip":"666006","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"Delta Research Partners - Bastrop","city":"Bastrop","state":"Louisiana","zip":"71220","country":"United States","geoPoint":{"lat":32.77828,"lon":-91.91144}},{"facility":"Louisiana Research Center","city":"Shreveport","state":"Louisiana","zip":"71105","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Mercy Medical Center","city":"Baltimore","state":"Maryland","zip":"21202","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Kansas City Research Institute","city":"Kansas City","state":"Missouri","zip":"64131","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Premier Health Research","city":"Sparta","state":"New Jersey","zip":"07871","country":"United States","geoPoint":{"lat":41.03343,"lon":-74.63849}},{"facility":"Lucas Research","city":"Morehead City","state":"North Carolina","zip":"28557","country":"United States","geoPoint":{"lat":34.72294,"lon":-76.72604}},{"facility":"Regional Gastroenterology Associates of Lancaster","city":"Flourtown","state":"Pennsylvania","zip":"19031","country":"United States","geoPoint":{"lat":40.10344,"lon":-75.2124}},{"facility":"Rapid City Medical Center","city":"Rapid City","state":"South Dakota","zip":"57701","country":"United States","geoPoint":{"lat":44.08054,"lon":-103.23101}},{"facility":"Premier Medical Group","city":"Clarksville","state":"Tennessee","zip":"37040","country":"United States","geoPoint":{"lat":36.52977,"lon":-87.35945}},{"facility":"Gastro One","city":"Cordova","state":"Tennessee","zip":"38018","country":"United States","geoPoint":{"lat":35.15565,"lon":-89.7762}},{"facility":"Texas Clinical Research Institute","city":"Arlington","state":"Texas","zip":"76012-3216","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"Pinnacle Clinical Research - Austin","city":"Austin","state":"Texas","zip":"78757","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"South Texas Research Institute - Brownsville","city":"Brownsville","state":"Texas","zip":"78520","country":"United States","geoPoint":{"lat":25.90175,"lon":-97.49748}},{"facility":"The Liver Institute at Methodist Dallas Medical Center","city":"Dallas","state":"Texas","zip":"75203","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Liver Center of Texas","city":"Dallas","state":"Texas","zip":"75234","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"South Texas Research Institute - Edinburg","city":"Edinburg","state":"Texas","zip":"78539","country":"United States","geoPoint":{"lat":26.30174,"lon":-98.16334}},{"facility":"Pinnacle Clinical Research - Georgetown","city":"Georgetown","state":"Texas","zip":"78626","country":"United States","geoPoint":{"lat":30.63269,"lon":-97.67723}},{"facility":"Houston Research Institute","city":"Houston","state":"Texas","zip":"77079","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Pinnacle Clinical Research - San Antonio","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Impact Research Institute","city":"Waco","state":"Texas","zip":"76710","country":"United States","geoPoint":{"lat":31.54933,"lon":-97.14667}},{"facility":"Digestive Health Research of Central Texas","city":"Waco","state":"Texas","zip":"76712","country":"United States","geoPoint":{"lat":31.54933,"lon":-97.14667}},{"facility":"GI Select Health Research","city":"Richmond","state":"Virginia","zip":"23236","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Hunter Holmes McGuire VA Medical Center","city":"Richmond","state":"Virginia","zip":"23249","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Liver Institute Northwest","city":"Seattle","state":"Washington","zip":"98105","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Latin Clinical Trials Center","city":"San Juan","zip":"00909","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"FDI Clinical Research (Fundacion de Investigacion de Diego)","city":"San Juan","zip":"00927","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}}]},"referencesModule":{"references":[{"pmid":"37786277","type":"DERIVED","citation":"Harrison SA, Ratziu V, Anstee QM, Noureddin M, Sanyal AJ, Schattenberg JM, Bedossa P, Bashir MR, Schneider D, Taub R, Bansal M, Kowdley KV, Younossi ZM, Loomba R. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2024 Jan;59(1):51-63. doi: 10.1111/apt.17734. Epub 2023 Oct 2."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D008103","term":"Liver Cirrhosis"}],"ancestors":[{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D005355","term":"Fibrosis"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C588408","term":"resmetirom"}]}},"hasResults":false}
]}